Abstract
Research Overview
Genetic Diagnostics Set to Revolutionize Healthcare Practices
The increased understanding of the genetic basis of disease and
genotype/phenotype correlation has allowed genetic diagnostics to become one
of the fastest growing segments in the healthcare industry. However, there are
challenges surrounding reimbursement, regulation, privacy, ethical issues, and
clinical validity. It has therefore become imperative to market the value
proposition of genetic diagnostics in terms of marked improvements in the
quality and efficiency of medical diagnosis and treatment. In the long run, as
clinicians realize the benefits of early detection and elimination of
redundant testing, they are likely to overlook the high costs of genetic
diagnostics and eventually increase adoption.
Clinicians Need for More Information with Regard to Therapeutic Treatment Drives Demand for Pharmacogenomic Testing
Pharmacogenomic testing is going to be a key driver for the uptake of genetic
diagnostics as clinicians strive to acquire high quality sensitive information
earlier on in the treatment process. "Healthcare practitioners across the
United States are working toward optimized medial treatment wherein the
patient has minimal if not zero side effects," say the analyst of this
research service. "There is no doubt that clinicians stand to benefit from the
vast amount of information available through genetic testing."
Manufacturers of genetic diagnostic tests must take on the responsibility of
educating clinicians about the benefits of pharmacogenomic testing in order to
ensure proper and maximum utilization of the tests at all levels in the
treatment process. For example, direct-to-consumer advertising or
presentations or workshops at medical conferences are likely to be vital in
educating the medical community on the use of genetic diagnostics.
Predictive Medicine Shows Immense Potential for Genetic Diagnostics
"Genetic tests are proving to be consistently in line with larger healthcare
goals of preventative and personalized medicine and the market will see
significant growth over the next seven years," observes the analyst. While
prenatal, newborn, and reproductive screening is the largest segment in the
market, predictive medicine shows huge potential for genetic diagnostics with
revenues expected to grow from $100.0 million in 2004 to $286.1 million in
2011.
Cancer diagnostic tests hold the largest share in the predictive medicine
market segment while other esoteric tests are likely to remain marginal
contributors to revenues. Oncologists are aware that the high severity of
adverse reactions caused by cancer and cancer drugs, combined with the high
mortality rates call for high value genetic tests. In the future, prices for
genetic testing can be expected to reduce to enable both reference
laboratories and diagnostic manufacturers to maintain desirable profit margins.
Table of Contents
- 1. Executive Summary
- 2. Total Market
- 1. Market Overview
- 1. U.S. Genetic Diagnostics Market Introduction
- 2. Market Definition and Segmentation Overview
- 3. Research Methodology
- 2. Market Analysis
- 1. Market Engineering Measurements
- 2. Industry Challenges
- 3. Strategic Recommendations
- 4. Regulatory Issues
- 3. Competitive Analysis
- 1. Competitive Structure and Market Share Analysis
- 2. Platform Comparison
- 3. End-user Profiles
- 4. Market Forecasts
- 3. Pharmacogenomic Testing Market
- 1. Market Overview
- 1. Introduction
- 2. Market Definition
- 2. Product Analysis
- 1. P450 and HER-2 Pharmacogenomic Tests
- 2. Cytochrome P450 Drug Interaction
- 3. Other Prominent Pharmacogenomic Tests
- 4. CYP450 Testing Platform Comparison
- 3. Market Analysis
- 1. Market Engineering Analysis
- 2. Pharmacogenomic Testing Market Drivers
- 3. Market Restraints
- 4. Competitive Analysis
- 1. Competitive Landscape Structure
- 2. Market Share Analysis
- 3. Customer Analysis
- 4. Market Impact Analysis
- 5. Market Forecasts
- 4. Prenatal and Newborn Genetic Screening Market
- 1. Market Overview
- 1. Market Overview
- 2. Market Definition
- 2. Market Analysis
- 1. Market Engineering Measurements
- 2. Market Drivers
- 3. Market Restraints
- 3. Competitive Analysis
- 1. Product Analysis
- 2. Competitive Structure and Market Share Analysis
- 4. Market Forecasts
- 5. Predictive Medicine Market
- 1. Market Overview
- 1. Introduction
- 2. Market Definition
- 2. Competitive Analysis
- 1. Predisposition and Diagnostic Products
- 2. Competitive Structure and Market Share Analysis
- 3. Market Analysis
- 1. Market Measurements
- 2. Market Drivers
- 3. Market Restraints
- 4. Market Forecasts
- 6. Decision Support Database
- 1. Supporting Statistical Data
- 1. Number and Types of Genetic Tests
- 2. Pharmacogenomic Information
- Chapter 2
- Total Genetic Diagnostic Market: Impact of Top Industry Challenges
(U.S.), 2004-2011
- Total Genetic Diagnostic Market: Impact of Top Industry Challenges on
Business Function (U.S.), 2004-2011
- Total Genetic Diagnostic Market: Strategic Recommendations (U.S.), 2004
- Total Genetic Diagnostic Market: Competitive Structure (U.S.), 2004
- Total Genetic Diagnostic Market: Products Offered by Major Market
Participants (U.S.), 2004
- Total Genetic Diagnostic Market: Revenue Forecasts (U.S.), 2001-2011.
- Chapter 3
- Pharmacogenomic Testing Market: List of CYP450 Isoform Drug Interaction
(U.S.), 2004
- Pharmacogenomic Testing Market: Product Analysis (U.S.), 2004
- Pharmacogenomic Testing Market: Market Drivers Ranked In Order of Impact
(U.S.), 2004-2011
- Pharmacogenomic Testing Market: Market Restraints Ranked In Order of
Impact (U.S.), 2004-2011
- Pharmacogenomic Testing Market: Competitive Structure (U.S.), 2004
- Pharmacogenomic Testing Market: Products Offered by Major Market
- Pharmacogenomic Testing Market: Drugs Pulled from Market Due to Adverse
Reactions (U.S.), 2004
- Pharmacogenomic Testing Market: Revenue Forecasts (U.S.) 2001-2011
- Chapter 4
- Prenatal and Newborn Genetic Screening Market: Market Drivers (U.S.),
2004-2011
- Prenatal and Newborn Genetic Screening Market: Risk of Downs Syndrome
vs. Maternal Age (U.S.), 2004
- Prenatal and Newborn Genetic Screening Market: Market Restraints (U.S.),
2004-2011
- Prenatal and Newborn Genetic Screening Market: Products Offered by Major
Market Participants (U.S.), 2004
- Prenatal and Newborn Genetic Screening Market: Common Tests for Each
Subsegment (U.S.), 2004
- Prenatal and Newborn Genetic Screening Market: Competitive Structure
(U.S.), 2004
- Prenatal and Newborn Genetic Screening Market: State Newborn Screening
Programs (U.S.), 2004
- Prenatal and Newborn Genetic Screening Market: Revenue Forecasts (U.S.),
2004
- Chapter 5
- Predictive Medicine Market: Products Offered by Major Market
Participants (U.S.), 2004
- Predictive Medicine Market: Competitive Structure (U.S.), 2004
- Predictive Medicine Market: Market Drivers (U.S.), 2004-2011
- Predictive Medicine Market: Market Restraints (U.S.), 2004-2011
- Predictive Medicine Market: Revenue Forecasts (U.S.), 2001-2011
- Chapter 6
- Decision Support Database: Number and Type of Genetic Tests (U.S.), 2004
- Decision Support Database: Safety Based Drug Withdrawals (U.S.), 2004
- Decision Support Database: Most Prescribed Drugs (U.S.) 2004
- Decision Support Database: Top Revenue Generating Drugs (U.S.) 2004
- List of Charts
- Chapter 2
- Total Genetic Diagnostics Market: Percent Revenues by Segment (U.S.),
2004
- Total Genetic Diagnostics Market: Market Engineering Measurements
(U.S.), 2004
- Total Genetic Diagnostics Market: Competitive Structure (U.S.), 2004
- Total Genetic Diagnostics Market: Company Market Share Revenue (U.S.),
2004
- Total Genetic Diagnostics Market: Technology Life Cycle (U.S.), 2004
- Total Genetic Diagnostics Market: Revenue Forecasts (U.S.), 2001-2011
- Total Genetic Diagnostics Market: Revenue Forecasts by Segment (U.S.),
2001-2011
- Chapter 3
- Pharmacogenomic Testing Market: Market Engineering Measurements (U.S.),
2004
- Pharmacogenomic Testing Market: Competitive Structure (U.S.), 2004
- Pharmacogenomic Testing Market: Test Market Share (U.S.), 2004
- Pharmacogenomic Testing Market: Effect of Testing on Market Size of Drug
(U.S.), 2004-2011
- Pharmacogenomic Testing Market: Revenue Forecasts (U.S.), 2001-2011
- Chapter 4
- Prenatal and Newborn Genetic Screening Market: Market Engineering
Measurements (U.S.), 2004
- Prenatal and Newborn Genetic Screening Market: Revenue Forecasts (U.S.),
2001-2011
- Chapter 5
- Predictive Medicine Market: Market Engineering Measurements (U.S.) 2004
- Predictive Medicine Market: Revenue Forecasts (U.S.), 2001-2011
バイオテクノロジー
その他のカテゴリ
FAQ